Triazine based radiopharmaceuticals and radioimaging agents
US9447121B2 · kind B2 · utility
9Cited by
15References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 10, 2014 |
| Grant date | Sep 20, 2016 |
| Priority date | — |
| Expiry date | Aug 12, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F5/003
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds according to Formula I and Formula II are potent inhibitors of PSMA.Pharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.